<code id='FB26EE5D14'></code><style id='FB26EE5D14'></style>
    • <acronym id='FB26EE5D14'></acronym>
      <center id='FB26EE5D14'><center id='FB26EE5D14'><tfoot id='FB26EE5D14'></tfoot></center><abbr id='FB26EE5D14'><dir id='FB26EE5D14'><tfoot id='FB26EE5D14'></tfoot><noframes id='FB26EE5D14'>

    • <optgroup id='FB26EE5D14'><strike id='FB26EE5D14'><sup id='FB26EE5D14'></sup></strike><code id='FB26EE5D14'></code></optgroup>
        1. <b id='FB26EE5D14'><label id='FB26EE5D14'><select id='FB26EE5D14'><dt id='FB26EE5D14'><span id='FB26EE5D14'></span></dt></select></label></b><u id='FB26EE5D14'></u>
          <i id='FB26EE5D14'><strike id='FB26EE5D14'><tt id='FB26EE5D14'><pre id='FB26EE5D14'></pre></tt></strike></i>

          Home / Wikipedia / comprehensive

          comprehensive


          comprehensive

          author:leisure time    Page View:5455

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In